News >

Pembrolizumab/Axitinib Improves Survival in Frontline RCC

OncLive Staff
Published: Thursday, Oct 18, 2018

Roger M. Perlmutter, MD, PhD

Roger M. Perlmutter, MD, PhD
Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the VEGF inhibitor axitinib (Inlyta) significantly improved survival versus sunitinib (Sutent) as a first-line treatment for patients with advanced or metastatic renal cell carcinoma (RCC), according to findings from the phase III KEYNOTE-426 trial.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication